-
1 month ago | 
rarecancernews.com | Marisa Wexler |Alice Melão
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a small Phase 1 clinical trial. The vaccine targets neoantigens, proteins able to trigger an immune response against a cancer, that were specific to each of the treated patients, all considered at high risk for disease recurrence.
-
2 months ago | 
rarecancernews.com | Marisa Wexler |Alice Melão
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of blood cancer, according to an interim analysis from an ongoing clinical trial.
-
Jan 13, 2025 | 
rarecancernews.com | Marisa Wexler |Andrea Lobo |Alice Melão
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia (AML), a type of blood cancer. This FDA status aims to speed developmental work on therapies for serious diseases with a need for new medications, with a goal of more quickly moving them through clinical trials and into a possible regulatory approval review.
-
Jan 7, 2025 | 
copdnewstoday.com | Caroline Gainer |Noah Greenspan |Marisa Wexler |Alice Melão
Those of us with chronic obstructive pulmonary disease (COPD) experience many physical changes. Some of these changes are inconsequential while others are significant. One of the more curious and seemingly inconsequential changes is in the frequency of my yawns. Although I can still yawn, I don’t feel the urge as often as I did before I was placed on supplemental oxygen for my COPD. Sources seem to disagree about why people yawn.
-
Nov 13, 2024 | 
charcot-marie-toothnews.com | Marisa Wexler |Alice Melão |Yedida Y Bogachkov |Shayna Korol
A team of U.S. researchers is calling for routine screening for hip dysplasia — when the bones in the hip joint don’t fit together correctly, causing instability — among children with Charcot-Marie-Tooth disease (CMT), after their work revealed it to be a common but underrecognized problem in young people with the inherited condition.
-
Oct 15, 2024 | 
parkinsonsnewstoday.com | Andrea Lobo |Margarida Maia |Steve Bryson |Alice Melão
Booster Therapeutics announced its launch and the start of work into therapeutics that improve the body’s ability to clear itself of the defective, disease-causing proteins that drive Parkinson’s disease and other neurodegenerative conditions. The company, which is based in Berlin and whose opening was supported by $15 million in seed financing, reports to have assembled an “extensive library” of compounds that it intends to use in developing potential small molecule clearance therapies.
-
Apr 17, 2024 | 
ancavasculitisnews.com | Andrea Lobo |Patricia Inacio |Alice Melão
Tavneos (avacopan) safely and effectively promotes clinical remission in people with newly diagnosed or relapsing ANCA-associated vasculitis (AAV), according to a multicenter, real-world study in the U.S.The remission rates after a year of treatment were higher than those in the Phase 3 ADVOCATE trial (NCT02994927), whose data supported Tavneos’s approval (84% vs. 65.7%).
-
Mar 5, 2024 | 
dravetsyndromenews.com | Lindsey Shapiro |Andrea Lobo |Alice Melão |Steve Bryson
Behavioral development in children and teens with Dravet syndrome generally held stable in the first year of an observational study, though some showed small improvements in communication, according to researchers.
-
Feb 27, 2024 | 
myelomaresearchnews.com | Mary Chapman |Patricia Inacio |Alice Melão |Joana Fernandes
Myeloma Action Month (MAM) is observed each March to call attention to multiple myeloma and the people affected by it, and this year’s event will focus on bringing hope to patients and caregivers through action. The international campaign is designed to improve awareness of myeloma among policymakers, researchers, public authorities, health professionals, and industry representatives, along with the general public.
-
Feb 12, 2024 | 
liverdiseasenews.com | Lindsey Shapiro |Marisa Wexler |Alice Melão |Joana Fernandes
Weekly injections of tirzepatide, an approved obesity and diabetes treatment, showed promise in people with nonalcoholic steatohepatitis (NASH) — now known as metabolic dysfunction-associated steatohepatitis or MASH — a serious form of fatty liver disease characterized by liver inflammation and scarring (fibrosis).
